SI
LAB icon

Symmetry Investments’s Standard BioTools LAB Stock Holding History

Symmetry Investments’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,000
Closed -$51.5K – 214
2024
Q1 		$51.5K Buy
+19,000
New +$45.9K ﹤0.01% 162

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Symmetry Investments's LAB Position: Q2 2024 in Review

Symmetry Investments sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 19,000 shares — an estimated $51.5K sold.

Symmetry Investments first reported a position in LAB in Q1 2024 and held it in 1 quarter. The position peaked at $51.5K in Q1 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

  • Symmetry Investments reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
  • Symmetry Investments sold 19,000 Standard BioTools shares in Q2 2024, an estimated $51.5K.
  • Symmetry Investments first reported a position in Standard BioTools in Q1 2024 and held it in 1 quarter.
  • Symmetry Investments's Standard BioTools position peaked at $51.5K in Q1 2024.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Symmetry Investments's 13F filing for Q2 2024, filed 13 Aug 2024.